Informations générales (source: ClinicalTrials.gov)
A Randomized Comparative Prospective Multicenter Study of the Efficacy of a Systematic Referral to Palliative Care of Patients Who Need for Palliative Care During an Unscheduled Visit in Comprehensive Anticancer Centers (PALLU)
Interventional
N/A
Centre Leon Berard (Voir sur ClinicalTrials)
août 2024
août 2026
10 janvier 2025
This is a randomized, multicenter, prospective, phase III study conducted in daily
emergency rooms of French Regional Comprehensive Cancer Centers.
In the standard arm, patients will be managed regardless of their PALLIA-10 score,
following conventional strategy. In the experimental arm, patients will be systematically
referred to a palliative care team.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 09/01/2025 11:32:11 | Contacter | |||
| CLCC RENE HUGUENIN INSTITUT CURIE | 09/01/2025 11:32:21 | Contacter | |||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CLCC INSTITUT GUSTAVE ROUSSY | Christine MATEUS, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Léon Bérard - 69008 - Lyon - France | Gisèle CHVETZOFF, MD,PhD | Contact (sur clinicalTrials) | |||
| ICM Val d'Aurelle - 34090 - Montpellier - France | Muriel THOMASO, MD | Contact (sur clinicalTrials) | |||
| Institut de Cancérologie de Lorraine - 54519 - Vandœuvre-lès-Nancy - France | Aline HENRY, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Male or female ≥ 18 years at the day of consenting to the study;
- Confirmed diagnosis of any type of solid or haematology tumours, with or without
Current oncological treatment, such as chemotherapy, immunotherapy, targeted
therapy, etc;
- Unscheduled admission in a French Regional Comprehensive Anti-Cancer Centre due to
an acute, unpredictable, intercurrent event related to cancer, its therapies or a
comorbidity;
- Patient for whom disease is considered as not curable;
- PALLIA-10 Score > 3/10;
- Willingness and ability to comply with the study requirements;
- Signed and dated informed consent indicating that the patient has been informed of
all the aspects of the trial prior to enrolment;
- Patient must be covered by a medical insurance.
- Male or female ≥ 18 years at the day of consenting to the study;
- Confirmed diagnosis of any type of solid or haematology tumours, with or without
Current oncological treatment, such as chemotherapy, immunotherapy, targeted
therapy, etc;
- Unscheduled admission in a French Regional Comprehensive Anti-Cancer Centre due to
an acute, unpredictable, intercurrent event related to cancer, its therapies or a
comorbidity;
- Patient for whom disease is considered as not curable;
- PALLIA-10 Score > 3/10;
- Willingness and ability to comply with the study requirements;
- Signed and dated informed consent indicating that the patient has been informed of
all the aspects of the trial prior to enrolment;
- Patient must be covered by a medical insurance.
- Patient without consciousness, unable to provide a written informed consent (context
of emergency);
- Patient treated with a curative intent;
- Previous randomization in this clinical study;
- Patients already followed-up by a palliative care team;
- Life expectancy shorter than 1 month, as per the emergency units' staff judgement.
- Any medical or psychosocial condition that would compromise the patient's compliance
to the study visits or would likely interfere with the completion of
Patient-Reported Outcomes.
- Patients under tutorship or curatorship.